𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Confocal endomicroscopy: a novel application for imaging of oral and oropharyngeal mucosa in human

✍ Scribed by Boris Rainer Haxel; Martin Goetz; Ralf Kiesslich; Jan Gosepath

Publisher
Springer-Verlag
Year
2009
Tongue
English
Weight
442 KB
Volume
267
Category
Article
ISSN
0302-9530

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Human tenascin-C: Identification of a no
Human tenascin-C: Identification of a novel type III repeat in oral cancer and of novel splice variants in normal, malignant and reactive oral mucosae
✍ Alan J. Mighell; John Thompson; William J. Hume; Alexander F. Markham; Philip A. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 French ⚖ 121 KB 👁 1 views

Tenascin-C is a mosaic, linear glycoprotein that is upregulated during many normal and pathological processes involving either cell migration or tissue morphogenesis, such as invasion of malignant cells and wound healing. Human tenascin-C contains 8 consecutive type III fibronectin (TNCfn) domains t

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Elena Marangon; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maur 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 149 KB

## Abstract CEP‐18770, [(1__R__)‐1‐{[(2__S__,3__R__)‐3‐hydroxy‐2‐{[(6‐phenyl‐2‐pyridinyl)carbonyl]amino}butanoyl]amino}‐3‐methylbutyl]boronic acid, is a novel proteasome inhibitor, now under early clinical evaluation as an anticancer agent. To investigate its clinical pharmacokinetics, a high‐perfo

Development and validation of a high-per
Development and validation of a high-performance liquid chromatography–tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study
✍ Federica Sala; Renzo Bagnati; Valeria Livi; Roberta Cereda; Maurizio D'Incalci; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

E‐3810, 6‐[[7‐[(1‐aminocyclopropyl)methoxy]‐6‐methoxy‐4‐quinolyl]oxy]‐__N__‐methyl‐naphthalene‐1‐carboxamide, is a novel, potent, dual inhibitor of vascular endothelial growth factor and fibroblast growth factor receptors with antiangiogenic properties, now under early clinical evaluation as an anti